CytomX Therapeutics, Inc.
(NASDAQ : CTMX)

( )
CTMX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.39%295.001.4%$597.51m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
-0.78%67.101.0%$366.91m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%372.162.6%$302.06m
VRTXVertex Pharmaceuticals, Inc.
0.25%220.551.9%$275.13m
CLVSClovis Oncology, Inc.
1.64%13.6514.7%$245.81m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-1.32%67.3211.4%$205.58m
ALXNAlexion Pharmaceuticals, Inc.
0.81%113.382.0%$204.43m
AAgilent Technologies, Inc.
1.73%84.861.6%$165.50m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
SRPTSarepta Therapeutics, Inc.
28.94%129.5514.6%$150.72m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BLUEbluebird bio, Inc.
-3.36%84.0514.2%$136.75m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.